Tempus AI, Inc. is trading 4.8% down at $47.23 as investors take profits following the announcement of a new digital pathology open-source consortium.
- The initiative, launched alongside Yale New Haven Health and Memorial Sloan Kettering Cancer Center, focuses on advancing AI-driven pathology and establishing data standardization.
- Despite the strategic significance of the partnership, the stock is facing downward pressure amid a broader retreat in U.S. equity markets and investor reassessment of recent valuation gains.